Q

Quest Diagnostics

Operates nationwide clinical laboratory testing

RPA Senior Specialist - Business Intelligence & Analytics

Full-TimeUpdated on 10/23/2026
$80k - $100k/yr+ 5% bonus
Senior
Bachelor's
Remote in USA
RemoteMust reside within commuting distance of a listed major lab in Kansas, Missouri, Colorado, Ohio, Indiana, or Illinois.
Data & AnalyticsData Analysis, Business Intelligence
No H1B Sponsorship

About the job

Requirements
  • At least 3 years of hands-on experience designing, developing, and implementing enterprise-scale robotic process automation solutions using UiPath; UiPath Advanced Developer certification is a plus.
  • At least 5 years of progressive, recent data science-related experience, including data analytics, business intelligence, dashboarding, data profiling, and data management.
  • At least 5 years of progressive, recent Python experience, including data analytics, business intelligence, dashboarding, data profiling, and data management.
  • Demonstrated strong experience in Power BI or Tableau for dashboard creation, data profiling, and visual data storytelling.
  • Proficiency in SQL and ETL tools; at least 1 year of Alteryx workflow development and experience with Snowflake are highly preferred.
  • At least 2 years of experience in the healthcare, diagnostics, or clinical laboratory industry is preferred.
  • Experience with Smartsheet workflow automation, portfolio tracking, and automated communication streams is an asset.
  • At least 2 years of experience with an intelligent automation platform such as Power Automate, UiPath, or generative AI.
  • At least 2 years of demonstrated business intelligence experience, including creating dashboards in Tableau, Power BI, or Looker and presenting data insights through visual data storytelling.
  • Demonstrated proficiency in SQL and ETL processes.
  • Expert-level capability in building, deploying, and managing attended and unattended automated bots and Studio workflows, with Orchestrator experience.
  • Strong ability to analyze complex operational datasets, such as specimen collection volumes, turnaround times, and onboarding lifecycles, and translate them into actionable business insights.
  • Exceptional skill in writing, tuning, and optimizing complex SQL queries and managing data pipelines.
  • Advanced skill in designing intuitive Power BI and Tableau dashboards using user interface and user experience best practices.
  • Ability to map current-state business workflows and design automated future-state processes.
  • Ability to communicate complex technical architectures and automated workflows to non-technical executive stakeholders.
  • Bachelor’s degree in Computer Science, Information Systems, Business Analytics, or a related quantitative field; equivalent work experience will be considered.
Responsibilities
  • Lead the end-to-end design, development, testing, deployment, and ongoing support of scalable, sustainable UiPath automation solutions to streamline business operations and eliminate manual data processing.
  • Lead the gathering and evaluation of complex business requirements for incoming analytics and workflow automation requests, translating them into effective technical solutions.
  • Lead the design, development, deployment, and maintenance of sustainable, automated business intelligence, reporting, and analytical dashboards using Tableau and Power BI; create scorecards, operational workflows, and interactive visualizations for regional leadership.
  • Design, develop, deploy, and support measurement algorithms using complex SQL scripts, stored procedures, and database queries, primarily in Snowflake and SQL Server.
  • Support database administration and datasets tracking client onboarding lifecycles, and manage complex parent-child account hierarchies for consolidated executive reporting.
  • Run and support monthly and ad hoc client reporting pipelines; investigate, troubleshoot, and resolve automated data processing and external system integration issues.
  • Partner with national teams, database administrators, and business stakeholders to execute project tasks, implement security protocols including row-level access controls, and maintain infrastructure stability.
  • Provide technical support for inbound and outbound eligibility feeds, develop dashboards, and generate custom reports for internal and external customers.
  • Provide advanced technical product support for Employer Population Health applications, working closely with internal and external customers.
  • Present findings and strategic output to leadership.
  • Drive results across cross-functional teams and coach junior developers on appropriate use of models, automated processes, and data standards.
Desired Qualifications
  • UiPath Advanced Developer certification.
  • At least 1 year of Alteryx workflow development and experience with Snowflake.
  • At least 1–2 years of experience in the healthcare, diagnostics, or clinical laboratory industry.
  • Experience with Smartsheet workflow automation, portfolio tracking, and automated communication streams.

About the company

Quest Diagnostics provides clinical laboratory testing and diagnostic services. It processes patient samples across a network of laboratories to run a broad menu of 3,000+ tests, including cancer diagnostics and anatomical pathology, and delivers interpretive reports through its medical staff. Tests are performed at its patient service centers, esoteric and rapid-response labs, and outpatient facilities, with results shared with clinicians via connected data systems. What sets Quest Diagnostics apart is its scale and scope: the world’s largest clinical lab network, the broadest test menu, a large team of MDs and PhDs for interpretation, and leadership in cancer diagnostics and pre-employment drug testing, plus extensive clinical trials testing. Its goal is to empower healthcare providers and patients with actionable diagnostic insights to identify, treat, and manage disease, inspire healthy behaviors, and improve health outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Secaucus, New Jersey

Founded

1967

Get referred to Quest Diagnostics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apple Health users will order Quest tests later in 2026, expanding direct-to-consumer reach.
  • Quest’s consumer-health business reached $250 million in 2025 and management targets 30% 2026 growth.
  • Quest will launch Roche pTau217 and its new multi-biomarker AD-Detect panel in Q4 2026.

What critics are saying

  • CMS cuts lab reimbursement up to 15% on January 1, 2027, hitting CMS revenue.
  • Quest faces NLRB case 14-CA-378210 over alleged discharge and coercive statements in St. Louis.
  • Repeated PAMA cuts and commoditized testing can squeeze Quest into a low-margin processing utility.

What makes Quest Diagnostics unique

  • Quest serves half of U.S. physicians and hospitals through 2,000 service centers.
  • Quest built a consumer-health platform with Apple Health, Oura, Hims & Hers, and Function Health.
  • Quest leads blood-based Alzheimer’s diagnostics with AD-Detect and Roche pTau217 launches in 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • 401(k) Company Match
  • Performance Bonus
  • Employee Stock Purchase Plan
  • Tuition Reimbursement
  • Wellness Program
  • Paid Vacation
  • Paid Holidays
  • Flexible Work Hours
  • 401(k) Retirement Plan

Company News

Yahoo Finance
Oct 23rd, 2026
Quest Diagnostics and Waters partner on at-home cervical cancer screening kit

Quest Diagnostics and Waters Corporation have announced a collaboration to expand access to the Onclarity Self-Collection Kit for cervical cancer screening. Patients collect samples at home, and Quest laboratories process them using the Onclarity HPV assay. The companies aim to widen access to testing for patients who face barriers to screening in clinics. The move supports Quest's push into consumer health testing, a business of roughly $300 million. Quest has a market value of about $26.9 billion. The program is due to enter broader rollout in 2027. Reimbursement pressure remains a risk for the company.

Yahoo Finance
Oct 22nd, 2026
Quest Diagnostics lifts 2026 guidance as Q3 revenue climbs 10%, warns of 1% PAMA hit

Quest Diagnostics reported 10% revenue growth in the third quarter of 2026 and raised its full-year revenue and earnings per share guidance. Growth came from physician, hospital, and consumer channels, and organic volume rose 5% excluding major partnerships. Hospital revenue grew by double digits, helped by the Corewell Health partnership. Consumer health revenue is expected to grow more than 30% this year, as users can now order labs through the Apple Health app. The company expects a 2027 hit of about 1% of revenue from cuts under the Protecting Access to Medicare Act (PAMA), and less than 1.3% cumulatively through 2029. It is backing the RESULTS Act to reform PAMA, and plans to offset part of the impact through efficiency gains. Quest also disclosed a cybersecurity incident at a test ordering system, which it said has not materially disrupted operations.

Yahoo Finance
Oct 22nd, 2026
Quest Diagnostics Q3 revenue rises 10% to $3.1B, beating estimates and lifting guidance

Quest Diagnostics (NYSE:DGX) beat Wall Street expectations in the third quarter, with revenue up 10% year on year to $3.1 billion. Analysts had expected $3.07 billion. Adjusted earnings per share were $3, 4.4% above estimates of $2.87 and up from $2.60 a year earlier. Sales volumes rose 14.5%, and operating margin climbed to 15.5% from 13.7%. The company raised its full-year adjusted EPS guidance to $11.30 at the midpoint. Full-year revenue guidance of $12.09 billion at the midpoint came in 0.6% above estimates. Chief executive officer Jim Davis credited strength across physician, hospital, and consumer channels, plus gains from automation and AI. Shares fell 1.8% to $234.67 after the results.

Yahoo Finance
Sep 22nd, 2026
Quest Diagnostics drops 5% as US cuts lab test reimbursement rates by 15%

Quest Diagnostics stock fell 5.1% on Tuesday after the Centers for Medicare and Medicaid Services announced it would cut reimbursement rates for lab work by up to 15%, effective 1 January 2027. CMS disclosed it has been paying approximately 16% more for lab tests than private insurers. The rate cuts could save taxpayers $1 billion annually but will reduce Quest's revenue. The company derives about 11% of its revenue from CMS reimbursement. If rates decrease by the full 15%, Quest's annual revenue would drop by 1.65%. Successive 15% annual reductions are possible through 2029, meaning a worst-case revenue reduction of slightly less than 5%. The company had warned in its SEC filing that Medicare and Medicaid rate changes posed risks to its business.

Citybiz
Sep 14th, 2026
Quanterix names yuri Fesko chief medical officer as diagnostics business expands.

Quanterix names yuri Fesko chief medical officer as diagnostics business expands. September 14, 2026 Dr. Yuri Fesko Quanterix Corporation has appointed Dr. Yuri Fesko chief medical officer, adding an experienced diagnostics executive as the company prepares for a broader market launch of its Lucent AD(R) Complete Alzheimer's disease test and advances regulatory work for its HD-X instrument. Fesko will provide medical and clinical leadership across the Nasdaq-listed precision biomarker company, working with its Diagnostics, Scientific, R&D, Regulatory and Commercial teams. He will be based at Quanterix's headquarters in Billerica, Massachusetts. The newly created role comes as Quanterix works to expand its diagnostics business and move more of its biomarker technologies into clinical applications. President and CEO Everett Cunningham said Fesko's background in clinical affairs and precision medicine will support both the commercialization of Lucent AD Complete and the company's planned IVD filing for HD-X. "As we prepare for the broader market launch of our Lucent AD Complete five biomarker test for Alzheimer's Disease, we welcome Dr. Yuri Fesko to Quanterix in an important new role to support our efforts to efficiently scale our expansion in diagnostics," Cunningham said. Fesko most recently served as chief medical officer at Quest Diagnostics, where he oversaw Medical Affairs, Clinical Development, Analytics and Public Health. He also served as the medical lead supporting the company's Quality and Regulatory functions and provided senior medical leadership for pathology and dermatopathology. His experience spans the development and implementation of precision medicine strategies in oncology, metabolic disease, neurology and consumer health. He has worked with health systems, pharmaceutical and biotechnology companies, and physician organizations to integrate precision diagnostics into clinical practice and clinical trials. Fesko also brings experience supporting FDA submissions, clinical development programs, companion diagnostic strategies and reimbursement planning. Those capabilities are relevant as Quanterix works to translate its biomarker research technologies into regulated diagnostic products and expand their use in clinical settings. One immediate priority is Lucent AD Complete, Quanterix's five-biomarker blood test for Alzheimer's disease. The company is preparing for a broader market launch of the test while simultaneously advancing the IVD regulatory filing for its HD-X instrument, making medical, regulatory and commercialization coordination a central part of Fesko's mandate. Cunningham said Fesko's ability to work across medicine, diagnostics, analytics and business strategy will support the company's efforts to build its Diagnostics business and broaden the clinical applications of its technology. Quanterix develops precision biomarker technologies designed to detect and quantify biological markers at very low concentrations. Its Simoa(R) platform provides high-sensitivity biomarker measurement in blood and other fluids, supporting applications across disease research, diagnostics and drug development. The company's technology portfolio has also expanded through its acquisition of Akoya Biosciences. Quanterix Spatial solutions provide high-plex quantitative protein analysis in tissue at single-cell resolution, adding spatial biology capabilities alongside its existing fluid biomarker technologies. Quanterix also operates Accelerator Laboratory services, providing researchers with additional capabilities for moving biomarker discoveries toward diagnostic applications. Together, those businesses give the company a platform spanning biomarker measurement, spatial analysis and laboratory services as it increases its focus on precision diagnostics. Fesko earned both his bachelor's degree and Doctor of Medicine from Case Western Reserve University and completed a fellowship at University Hospitals of Cleveland. He is board-certified in internal medicine, hematology and medical oncology. His appointment adds senior clinical leadership at a point when Quanterix is managing both product commercialization and regulatory execution. As the company expands beyond research applications, Fesko will help coordinate the medical evidence, regulatory strategy and clinical adoption required to move its biomarker technologies more broadly into diagnostic workflows.